Ticagrelor vs Clopidogrel and Adverse Events in Patients With Acute Coronary Syndrome Undergoing PCI
This cohort study compares net risk for ischemic vs hemorrhagic events at 12 months among patients treated with ticagrelor vs clopidogrel during and after percutaneous coronary intervention (PCI) management of acute coronary syndrome (ACS).
Source: JAMA - Category: General Medicine Source Type: research
More News: Angioplasty | Clopidogrel | Coronary Angioplasty | General Medicine | Percutaneous Coronary Intervention | Plavix | Study